Orexo AB Takes Large Step Forward on the Road to Improve Treatment for People Dependent on Opioid Pain Killers
7/2/2012 10:57:08 AM
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (“Orexo”) has ahead of schedule completed a crucial comparative bioavailability study for its product OX219. The market in the US alone for this type of treatment for people addicted to opioid pain killers, amounted to USD 1.3 bn in 2011. The study, which met the expectations of the key pharmacokinetic parameters, was completed on June 30 and is the final clinical study as discussed with the FDA, which means that all pivotal clinical data has now been generated. In the study, OX219 was tested against brand leader Suboxone®, where it demonstrated both comparative bioavailability for the two active ingredients as well as positive results for product attributes which are important from the patient’s perspective.